A Study of AMC6156 in People With Sarcopenia
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age65+
SponsorAnimuscure Inc.
About this trial
This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.
Eligibility criteria
Qualifiers
Voluntary participation with written informed consent
Male ≥ 65 years or postmenopausal female
ASM < 7.0 kg/m² (men) or < 5.4 kg/m² (women)
Plus low handgrip strength or SPPB ≤ 9
Disqualifiers
Allergy to investigational drug
History of GI bleeding, ulcers, or severe liver/kidney/heart disease
QTc ≥ 450 ms with symptoms
Severe COPD, uncontrolled diabetes or thyroid disease
Trial design
Treatments tested in this trial
- AMC6156 0.1mg
- AMC6156 0.3mg
- AMC6156 1.0mg
- Placebo
Treatment groups
80 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov